In continuation with its commitment to multiple sclerosis (MS) patients in India, Biogen Idec has announced the introduction of Tysabri the first humanized, monoclonal antibody for the treatment of relapsing remitting MS in India.
Tysabri inhibits adhesion molecules on the surface of immune cells. Research suggests it works by preventing immune cells from migrating from the bloodstream into the brain where they can cause inflammation and potentially damage nerve fibers and their insulation.
?We believe Tysabri will be an important treatment option to help address the high unmet need of those living with MS in India. MS is a devastating disease that affects people in the prime of their lives. We are pleased to bring this important therapy to the MS community,? said Alpna Seth, managing director Biogen Idec, India.
MS is a chronic, progressive, and unpredictable inflammatory disease of the central nervous system (CNS). It primarily affects people between 20 – 40 years of age, and it is seen more frequently in women than men. In India, the exact number of MS patients is unknown.